The Biden administration announced on Thursday that the Department of Health and Human Services has reached agreements with top drugmakers to lower drug prices for the first 10 drugs included in the Centers for Medicare & Medicaid Services' Medicare Drug Price Negotiation Program under the Inflation Reduction Act.

The drug list, which includes some of the most popular drugs used by millions of older Americans to help manage diabetes, blood cancers and prevent heart failure or blood clots, includes:

• Eliquis, a blood thinner (Bristol Myers Squibb/Pfizer)
• Xarelto, a blood thinner (Johnson & Johnson)
• Januvia, a diabetes drug (Merck)
• Jardiance, a diabetes drug (Boehringer Ingelheim/Eli Lilly)
• Enbrel, a rheumatoid arthritis drug (Amgen)
• Imbruvica, a drug for blood cancers (AbbVie/J&J)
• Farxiga, a drug for diabetes, heart failure and chronic kidney disease (AstraZeneca)
• Entresto, a heart failure drug (Novartis)
• Stelara, a drug for psoriasis and Crohn's disease (J&J)
• NovoLog, for diabetes (Novo Nordisk)

The drug discounts, agreed to after months of negotiations with drug manufacturers which began last October, range between 38% and 79%. That is the medication's cost before any discounts or rebates are applied, but not what the price people actually pay when filling their prescriptions. For example, the negotiated price for a 30-day supply of Eliquis was reduced from $521 to $231. The new pricing will take effect in 2026.